Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis: Evidence from the psocare project

Dermatology

Volumn 217, Issue 4, 2008, Pages 365-373

  Naldi, Luigi ^a   Addis, Antonio ^d   Chimenti, Sergio ^f   Giannetti, Alberto ^c   Picardo, Mauro ^e   Tomino, Carlo ^d   Maccarone, Mara ^g   Chatenoud, Liliane ^a,b   Bertuccio, Paola ^a,b   Caggese, Eugenia ^a   Cuscito, Rosanna ^d   Venegoni, Mauro ^h  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d Italian Drug Agency(AIFA)   (Italy)

^e Istituti Fisioterapici Ospitalieri Rome   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g Italian Psoriatic Patient Association (ADIPSO)   (Italy)

^h NONE

Author keywords

Body mass index; Epidemiology, psoriasis; Prognosis, psoriasis; Systemic therapy

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PSORALEN; SALAZOSULFAPYRIDINE; STEROID;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; RATING SCALE; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ADULT; BODY MASS INDEX; COHORT STUDIES; FEMALE; HUMANS; INTERNET; ITALY; MALE; MIDDLE AGED; OBESITY; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 52049110303     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000156599     Document Type: Article

References (35)

1. Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121-128.
2. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y: The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383-392.
3. Dellavalle RP, Johnson KR: Do smoking, obesity, and stress cause psoriasis? J Invest Dermatol 2005;125:vi-vii.
4. Lebwohl M, Callen JP: Obesity, smoking, and psoriasis. JAMA 2006;295:208-210.
5. Huerta C, Rivero E, Rodríguez LA: Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007;143:1559-1565.
6. Setty AR, Curhan G, Choi HK: Obesity, waist circumference, weight change, and the risk of psoriasis in women. Arch Intern Med 2007;167:1670-1675.
7. Sterry W, Strober BE, Menter A, International Psoriasis Council: Obesity in psoriasis: the metabolic, clinical and therapeutic implications - report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649-655.
8. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-835.
9. Gelfand JM, Neimann AL, Shin, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741.
10. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J: Association between psoriasis and the metabolic syndrome: a cross-sectional study. Dermatology 2008;216:152-155.
11. Kimball AB, Robinson D Jr, Wu Y, Guzzo C, Yeilding N, Paramore C, Fraeman K, Bala M: Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008;217:27-37.
12. Boffetta P, Gridley G, Lindelof B: Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531-1537.
13. Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS: Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 2006;126:1480-1489.
14. Sakai R, Matsui S, Fukushima M, Yasuda H, Miyauchi H, Miyachi Y: Prognostic factor analysis for plaque psoriasis. Dermatology 2005;211:103-106.
15. Stern RS: A promising step forward in psoriasis therapy. JAMA 2003;290:3133-3135.
16. Bongartz T, Sutton AJ, Sweeting MJ, et al: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275-2285.
17. Psocare: Assessment of the outcomes concerning the treatment of psoriasis in Italy. BIF 2004;XI:189-193.
18. Gehan EA, George SL: Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970;54:225-235.
19. EMEA Committee for proprietary medical products (CPMP): Note for guidance on clinical investigation of medicinal products indicated for the treatment of psoriasis. CPMP/EWP/2454/02.
20. Breslow NE, Day NE: Statistical Methods in Cancer Research. 1. The Analysis of Case Control Studies. IARC Sci Publ No 32. Lyon, IARC, 1980.
21. Agenzia Italiana del Farmaco: Res. June 13, 2005. Gazzetta Ufficiale No. 146, published June 25, 2005.
22. Herron MD, Hinckley M, Hoffman M, et al: Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2007;141:1527-1534.
23. Naldi L, Svensson A, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, Bavinck JN, Williams H, European Dermato-Epidemiology Network: Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003;120:738-741.
24. Lindegard B: Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304.
25. Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-986.
26. Naldi L, Chatenoud L, Linder D, et al: Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-67.
27. Bjorntorp P: Obesity. Lancet 1997;350:423-436.
28. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006;444:860-867.
29. Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T: T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf) 2001;54:347-354.
30. Altinova AE, Toruner F, Bozkurt N, Bukan N, Karakoc A, Yetkin I, Ayvaz G, Cakir N, Arslan M: Circulating concentrations of adiponectin and tumor necrosis factor-alpha in gestational diabetes mellitus. Gynecol Endocrinol 2007;23:161-165.
31. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, Gedrich K, Pollmacher T: TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. Eur Cytokine Netw 2006;17:196-201.
32. Kjeldsen-Kragh J, Haugen M, Borchgrevink CF, et al: Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. Lancet 1991;338:899-902.
33. Lithell H, Bruce A, Gustafsson IB, et al: A fasting and vegetarian diet treatment trial on chronic inflammatory disorders: effects on clinical condition and serum levels of neutrophil-derived granule proteins. Acta Derm Venereol (Stockh) 1983;63:397-403.
34. De Menezes Ettinger JE, Azaro E, de Souza CA, dos Santos Filho PV, Mello CA, Neves M Jr, de Amaral PC, Fahel E: Remission of psoriasis after open gastric bypass. Obes Surg 2006;16:94-97.
35. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB: Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006;67:768-773.